System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Studies

Observational Not yet recruiting

NCT05569356 on ClinicalTrials.gov

Diagnostic Contribution, Prognosis and Physiopathological Aspects in Arrhythmogenic Cardiomyopathy. (ACORE)

Official title: Biomarkers of Inflammation and Autoimmunity: Diagnostic Contribution, Prognosis and Physiopathological Aspects in Arrhythmogenic Cardiomyopathy.

  • Sponsor: Assistance Publique - Hôpitaux de Paris
  • Enrollment: 300 (Estimated)
  • Study start: 2022-10-20 (Estimated)
  • Primary completion: 2032-10-20 (Estimated)
  • Study completion: 2032-10-20 (Estimated)
  • Allocation: N/a
  • InterventionModel: N/a
  • Masking: None
  • PrimaryPurpose: Other

Brief Summary

This study aims to identify novel inflammatory biomarkers in AC, whether in circulating blood, in situ or as imaging biomarkers to better understand the pathophysiology of the disease and then to determine contribution to the clinical management of patients.

Conditions

  • Arrhythmogenic Cardiomyopathy

Intervention / Treatment

  • Biological: Prospective
  • Other: Retrospective

Primary Outcome Measures

  • Measure the correlation between the autoimmunity, inflammatory, and immunological profiles through biomarkers found in blood samples, myocardial biopsies, mass imaging cytometry, and cardiac imaging in patients with Arrhythmogenic Cardiomyopathy (AC) (10 years)

Countries

France

Locations and Investigators

  • Institut de Cardiologie de la Pitié-Salpêtrière, Paris, France

Study Officials